Fatty Liver Disease Research Dashboard
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 50 studies associated with Fatty Liver Disease.
Here is a small sampling of Fatty Liver Disease studies by title:
- New peripherally-restricted CB1 receptor antagonists, PMG-505-010 and -013 ameliorate obesity-associated NAFLD and fibrosis
- Serum anandamide level as a potential indicator for nonalcoholic fatty liver disease severity
- Expression of NF-κB, IL-6, and IL-10 genes, body composition, and hepatic fibrosis in obese patients with NAFLD-Combined effects of oleoylethanolamide supplementation and calorie restriction: A triple-blind randomized controlled clinical trial
- Phytocannabinoids—A Green Approach toward Non-Alcoholic Fatty Liver Disease Treatment
- The Effect of CB1 Antagonism on Hepatic Oxidative/Nitrosative Stress and Inflammation in Nonalcoholic Fatty Liver Disease
Components of the Fatty Liver Disease Research Dashboard
- Dosing information available for Fatty Liver Disease
- Chemotype guidance for treating Fatty Liver Disease with cannabis
- Synopsis of cannabis research for Fatty Liver Disease
- Individual study details for Fatty Liver Disease
Ready to become a subscriber? Go to our PRICING page.
Fatty Liver Disease Research Dashboard
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 50 studies associated with Fatty Liver Disease.
Here is a small sampling of Fatty Liver Disease studies by title:
- New peripherally-restricted CB1 receptor antagonists, PMG-505-010 and -013 ameliorate obesity-associated NAFLD and fibrosis
- Serum anandamide level as a potential indicator for nonalcoholic fatty liver disease severity
- Expression of NF-κB, IL-6, and IL-10 genes, body composition, and hepatic fibrosis in obese patients with NAFLD-Combined effects of oleoylethanolamide supplementation and calorie restriction: A triple-blind randomized controlled clinical trial
- Phytocannabinoids—A Green Approach toward Non-Alcoholic Fatty Liver Disease Treatment
- The Effect of CB1 Antagonism on Hepatic Oxidative/Nitrosative Stress and Inflammation in Nonalcoholic Fatty Liver Disease
Components of the Fatty Liver Disease Research Dashboard
- Dosing information available for Fatty Liver Disease
- Chemotype guidance for treating Fatty Liver Disease with cannabis
- Synopsis of cannabis research for Fatty Liver Disease
- Individual study details for Fatty Liver Disease
Ready to become a subscriber? Go to our PRICING page.
Select New Condition
Overview - Fatty Liver Disease
Description of Fatty Liver Disease
There are two broad categories of fatty liver disease, also known as hepatic steatosis: alcoholic fatty liver disease (AFLD) and non-alcoholic fatty liver disease (NAFLD). NAFLD is further divided into two subtypes: non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH).
NAFL is generally considered a benign form, characterized by excess fat accumulation in the liver without significant inflammation or liver cell damage. NASH, however, involves not only fat buildup but also inflammation and hepatocellular injury, which can progress to fibrosis, cirrhosis, esophageal varices, hepatic insufficiency, or hepatocellular carcinoma if left untreated.
Fatty liver disease is typically a chronic and often silent condition. Many individuals remain asymptomatic for years. When present, symptoms may include vague discomfort or pressure in the right upper abdominal quadrant, fatigue, or generalized weakness. In advanced stages, signs of liver dysfunction may appear.
Contributing factors recognized in conventional medicine include:
- Obesity, metabolic syndrome, and hyperlipidemia
- Type 2 diabetes
- Alcohol use (in AFLD), or even modest intake in some NAFLD cases
- Poor nutrition (especially high fructose and processed diets)
- Hepatitis C infection
- Inflammatory bowel disease (IBD)
- Hypertension
- Long-term use of certain medications, including corticosteroids, methotrexate, amiodarone, antiretrovirals, and tamoxifen
The prevalence of NAFLD has been steadily rising worldwide and now affects an estimated 20–30% of the U.S. population, with even higher rates in populations with obesity or diabetes.
As with other preventable chronic diseases, patient education, early detection, and lifestyle modification are critical. First-line interventions typically include:
- Nutritional counseling and adopting a Mediterranean-style or low-glycemic diet
- Weight loss (targeting 7–10% body weight reduction)
- Regular physical activity
- Avoidance of alcohol and smoking
Currently, there is no FDA-approved pharmacotherapy for NAFLD or NASH, but ongoing research explores the endocannabinoid system, PPAR agonists, insulin sensitizers, and anti-inflammatory agents as possible future treatments.
Disease Classification
Condition: Fatty Liver DiseaseDisease Family: Fatty Liver disease
Organ System: Digestive System
ICD-10 Chapter: Diseases of the Digestive System
ICD-10 Code: K76.0
Fatty Liver Disease Symptoms:
Enlarged liver (evident on physical exam or by ultrasound), upper right abdominal discomfort/pain, generalized weakness, jaundice, nausea, ascites, male breast development, red palms, obesity, metabolic syndromeAlso known as:
FLD, NAFLD, Hepatic SteatosisDrug Interactions
THC Interaction with Pharmaceutical Drugs
- Tetrahydrocannabinol (THC) can enhance the effects of drugs that cause sedation and depress the central nervous system, such as benzodiazepines, barbiturates, and alcohol.
- THC is metabolized by an inhibitor of several enzymatic liver pathways referred to as cytochrome P450 (aka CYP450). There are more than 50 enzymes belonging to this enzyme family, several of which are responsible for the breakdown of common drugs such as antidepressants (e.g., amitriptyline, doxepin, fluvoxamine), antipsychotics (haloperidol, clozapine, Stelazine), beta-blockers (e.g., propranolol), bronchodilators (e.g., theophylline), or blood thinners (e.g., warfarin). Thus, patients taking these medication classes may find that THC increases the concentration and effects of these drugs and the impact duration.
- Clinical observation (not yet confirmed by clinical trials) suggests no likely interactions with other pharmaceuticals at a total daily dose of up to 20mg THC.
If you are interested in the interaction potential of specific pharmaceuticals with THC, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.
CBD Interaction with Pharmaceutical Drugs
- Cannabidiol (CBD) may alter the action of metabolic enzymes (specific drug-transport mechanisms) and alter interactions with other drugs, some of which may produce therapeutic or adverse effects. For instance, CBD interacts with the enzyme cytochrome P450 3A4 and cytochrome P450 2C19, increasing the bioavailability of anti-epileptic drugs such as clobazam (a benzodiazepine). This makes it possible to achieve the same results at significantly lower dosages, reducing treatment costs and risks of adverse effects.
- Groups of drugs affected include anti-epileptics, psychiatric drugs, and drugs affecting metabolic enzymes.
- Clinical observations (not yet confirmed by clinical trials) suggest no likely interactions with other pharmaceuticals at a total daily dose of up to 100mg CBD.
If you are interested in the interaction potential of specific pharmaceuticals with CBD, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.
THC/CBD Interaction with Pharmaceutical Drugs
In general, when using cannabinoid-based therapeutics that contain both THC and CBD consider the ratio between them and weigh the relevant information displayed in the individual THC and CBD Drug Interaction windows accordingly.
If you are interested in the interaction potential of specific pharmaceuticals with both primary cannabinoids and THC/CBD, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.
Concerns about Cannabis and Cancer-related Immunotherapies:
Some recent clinical observational studies have suggested that the co-administration of cannabinoid-based therapeutics and immunotherapy or immune checkpoint inhibitors in the treatment of certain types of cancer has been associated with worse overall survival rates (T. Taha et al., 2019; A. Biedny et al., 2020; G. Bar-Sela et al., 2020).
However, other studies have suggested that the co-commitment use of immune checkpoint inhibitors and cannabis-induced no such deleterious effects. More specifically, one trial was conducted on animals resulting in data suggesting that cannabis did not negatively affect the properties of immune checkpoint inhibitors (B. Waissengrin et al., 2023). The same authors compared the previous study results with findings from a cohort of 201 patients with metastatic non-small cell lung cancer who received treatment with monotherapy pembrolizumab as a first-line treatment and adjunct cannabis to treat mainly pain and loss of appetite. Their time to tumor progression was 6.1 versus 5.6 months, and overall survival differed between 54.9 versus 23.6 months in cannabis-naïve patients and cannabis-using patients, respectively. However, while numerically different, the authors write that these differences were not statistically significant, leading them to suggest that “These data provide reassurance regarding the absence of a deleterious effect of cannabis in this clinical setting.”
Dosing Considerations
THC Dosage Considerations
- THC micro dose: 0.1 mg to 0.4 mg
- THC low dose: 0.5 mg to 5 mg
- THC medium dose: 6 mg to 20 mg
- THC high dose: 21 mg to 50+ mg
CBD Dosage Considerations
- CBD low dose: 0.4 mg to 19 mg
- CBD medium dose: 20 mg to 99 mg
- CBD high dose: 100 mg to 800+ mg (upper limits tested ~1,500mg)
Disclaimer
Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own licensed physician or other medical professional. You
should not use the information contained herein for diagnosing or treating a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a
medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.
